IMIC(SZ:000516)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥304,865,465.75, a decrease of 51.78% compared to ¥632,244,259.12 in the same period last year[2] - The net profit attributable to shareholders was -¥428,421,595.49, representing a decline of 134.01% from -¥183,074,645.82 year-on-year[2] - The net cash flow from operating activities was -¥206,292,285.65, a significant decrease of 410.92% compared to ¥66,349,139.44 in the previous year[2] - Total operating revenue for Q1 2022 was CNY 304,865,465.75, a decrease of 51.8% compared to CNY 632,244,259.12 in the same period last year[13] - Net loss for Q1 2022 was CNY 432,820,830.09, compared to a net loss of CNY 185,159,657.65 in Q1 2021, indicating a significant increase in losses[14] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.1882, compared to CNY -0.0950 in the same period last year[15] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,888,019,415.82, down 3.25% from ¥13,320,275,545.21 at the end of the previous year[2] - The total assets decreased to CNY 12,888,019,415.82 from CNY 13,320,275,545.11 year-on-year[12] - The company's total liabilities decreased to CNY 7,938,186,655.74 from CNY 7,988,793,342.79 in the previous quarter[12] - The equity attributable to shareholders decreased by 7.08% to ¥4,948,267,140.76 from ¥5,325,517,348.40 at the end of the previous year[2] Cash Flow - The company's cash and cash equivalents decreased to ¥875,238,476.85 from ¥1,519,625,597.33, representing a decline of approximately 42.4%[10] - Cash inflow from investment activities totaled 395,951,934.84 RMB, down from 962,954,430.30 RMB in the prior period[17] - The net cash flow from financing activities was -27,939,026.41 RMB, compared to a positive 1,264,919,771.87 RMB in the previous period[17] - The total cash and cash equivalents at the end of the period were 875,238,476.85 RMB, down from 1,738,754,303.66 RMB at the beginning of the period[18] - The total cash outflow from operating activities was 573,267,605.86 RMB, slightly decreased from 585,782,097.73 RMB in the prior period[17] Operational Changes - The company reported a 51.78% decrease in operating revenue primarily due to the suspension of operations at subsidiaries Xi'an International Medical Center and Xi'an High-tech Hospital[4] - The company signed a framework agreement to transfer 99% equity of Shangluo International Medical Center Hospital, indicating a strategic move towards divestment[9] - The company’s stock was placed under risk warning and renamed to "ST Guoyi" due to operational disruptions, with a trading limit of 5%[8] - The company’s stock risk warning was lifted on April 18, 2022, allowing for a trading limit increase to 10%[9] Expenses - The company experienced a 30.09% increase in financial expenses, mainly due to interest expenses from its subsidiary[4] - Total operating costs for Q1 2022 were CNY 719,638,761.44, slightly down from CNY 742,690,177.83 year-on-year[13] - Research and development expenses for Q1 2022 were CNY 2,358,282.37, a slight decrease from CNY 2,593,910.77 in the previous year[13] - The company reported a significant increase in tax expenses, totaling CNY 7,047,554.79 in Q1 2022, compared to CNY 4,678,301.98 in Q1 2021[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 136,877, with the largest shareholder holding 29.74% of the shares[5] Audit Information - The company did not conduct an audit for the first quarter report[18]